Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion.

ABSTRACT: Among the various types of breast cancer, the luminal B subtype is the most common in young women, and ESR1-CCDC170 (E:C) fusion is the most frequent oncogenic fusion driver of the luminal B subtype. Nevertheless, treatments targeting E:C fusion has not been well established yet. Hence, the aim of this study is to investigate potential therapies targeting E:C fusion based on systematic bioinformatical analysis of the Cancer Genome Atlas (TCGA) data. One thousand related genes were extracted using transcriptome analysis, and major signaling pathways associated with breast cancer were identified with over-representation analysis. Then, we conducted drug-target network analysis based on the OncoKB and CIViC databases, and finally selected potentially applicable drug candidates. Six major canc

SUBMITTER: Jeong JH 

PROVIDER: S-EPMC7913953 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature